Overall, the time-response killing curves obtained following pathway sensitization with SW IV-134 closely mimic the dose-response activity profiles for the respective TR3 drugs when used alone (compare Figure 2C) and highlight the benefits of tethering TR3-based therapeutics to the cancer cells via the high-affinity interaction between mesothelin and MUC16. The gene discussed is MUC16; the disease is cancer.